Table 2 Analyses of the associations of sCD73 activity and overall survival
From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Univariate | Multivariate | |
|---|---|---|
HR (95% CI) P value | HR (95% CI) P value | |
Gender (M vs. F) | 2.08 (0.80–5.38) P = 0.13 | n.s. |
Age, years (≥ 62 vs. < 62) | 1.09 (0.45–2.65) P = 0.85 | n.s. |
BRAF status (mut vs. wt) | 0.53 (0.19–1.48) P = 0.22 | n.s. |
LDH, IU/L (≥ 480 vs. < 480) | 2.72 (1.07–6.88) P = 0.03 | n.s. |
Line of treatment (> 2 vs. 2) | 2.38 (0.96–5.94) P = 0.06 | n.s. |
Brain METS (yes vs. no) | 1.04 (0.35–3.12) P = 0.94 | n.s. |
Basal sCD73 activity (≥ 27.8 vs. < 27.8) | 6.27 (2.17–18.11) P = 0.001 | 6.27 (2.17–18.11) P = 0.001 |